
Become part of a vital chain and contribute to our common goal of making people’s lives better. Octapharma is one of the largest human protein manufacturers in the world, developing and producing medicines sourced from human plasma and human cell lines. We are a privately-owned company, where the warmth of family meets the scale of a global organisation.
With over 1700 employees, the Octapharma site in Vienna is the largest production site, and successful research and development location.
This position is temporary until 30.04.2028
Enjoy these attractive benefits! You can find all offers here: Benefits
The minimum gross salary according to the collective agreement (chemical industry) is EUR 4.270,14 based on 38 hours per week (full-time). As we strive to offer a salary that reflects your individual profile and qualifications, there is a willingness to pay above the minimum salary.
We live diversity and stand for equal opportunities as an employer! We therefore look forward to receiving your application - regardless of age, gender, origin, sexual orientation, and religion.
Do you have any questions? Then get in touch with your contact person.
Mrs. Johanna Proksch, MA
Octapharma Pharmazeutika Produktionsges.m.b.H.
Oberlaaer Straße 235, 1100 Wien
T: +43 (1) 610 32 - 4299
Visit our website Octapharma Career and follow us daily on LinkedIn

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines.
Octapharma employs more than 11,000 people worldwide to support the treatment of patients in 120 countries with products across three therapeutic areas: Immunotherapy, Haematology and Critical Care.
Octapharma has seven R&D sites and five state-of-the-art manufacturing facilities in Austria, France, Germany and Sweden, and operates over 195 plasma donation centres across Europe and the US. Octapharma has more than 40 years of experience in patient care.
Check our community guidelines: https://bit.ly/3M8ioml